Amphista Therapeutics

Amphista logo

Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Contact Amphista via their website

News archive

28/06/2021   Amphista Therapeutics Appoints New Head of Drug Discovery and Director of Chemistry...more

17/03/2021   Amphista Raises $53m in oversubscribed series b round...more

27/01/2021   Amphista blog: It's not Rocket Science...more

02/02/2021   Meet Amphista at 7 upcoming digital events...more

04/01/2020   Meet Amphista at Biotech showcase 11-15th January...more

01/11/2020   Amphista joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code